23.22
0.01 (0.04%)
| Previous Close | 23.21 |
| Open | 23.30 |
| Volume | 202,316 |
| Avg. Volume (3M) | 817,124 |
| Market Cap | 1,075,195,136 |
| Price / Earnings (Forward) | 9.49 |
| Price / Sales | 1.75 |
| Price / Book | 1.59 |
| 52 Weeks Range | |
| Earnings Date | 28 Jul 2025 - 1 Aug 2025 |
| Profit Margin | -14.76% |
| Operating Margin (TTM) | 4.63% |
| Diluted EPS (TTM) | -2.24 |
| Quarterly Revenue Growth (YOY) | 1.10% |
| Quarterly Earnings Growth (YOY) | -46.40% |
| Total Debt/Equity (MRQ) | 79.70% |
| Current Ratio (MRQ) | 2.41 |
| Operating Cash Flow (TTM) | 175.75 M |
| Levered Free Cash Flow (TTM) | 144.75 M |
| Return on Assets (TTM) | 3.56% |
| Return on Equity (TTM) | -12.27% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
| Stock | Pacira BioSciences, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 4.0 |
| Average | 0.75 |
|
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 1.79% |
| % Held by Institutions | 110.89% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Aug 2025 | Announcement | Pacira BioSciences Reports Second Quarter 2025 Financial Results |
| 24 Jul 2025 | Announcement | Pacira to Report Second Quarter 2025 Financial Results on Tuesday August 5, 2025 |
| 22 Jul 2025 | Announcement | Pacira BioSciences Announces Strategic Collaboration to Significantly Expand ZILRETTA Promotional Efforts |
| 03 Jul 2025 | Announcement | Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 18 Jun 2025 | Announcement | Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient’s Journey to Pain Relief and Innovation in Care at BIO 2025 |
| 11 Jun 2025 | Announcement | Pacira BioSciences Unveils Three-Year Clinical Data Following a Single Local Administration of Investigational Gene Therapy, PCRX-201, in Patients with Moderate-to-Severe Osteoarthritis of the Knee |
| 05 Jun 2025 | Announcement | Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |